Latest Strategic Capital Raising News

Surefire Resources NL has launched a non-renounceable entitlement offer aiming to raise approximately A$3.87 million to advance its gold and copper projects in Western Australia. The offer includes new shares, bonus shares, and options, targeting eligible shareholders in Australia and New Zealand.

Auric Mining Ltd has unveiled a capital raising plan aimed at boosting gold production and expanding its resource base through 2028, including key acquisitions and exploration initiatives.

Catalyst Metals Limited has secured A$150 million in equity to fund organic growth and exploration across its flagship Plutonic Gold Belt and Bendigo Gold Belt projects. The company aims to nearly double gold production to around 200,000 ounces per annum while reducing costs through strategic acquisitions and infrastructure leverage.

Catalyst Metals has raised $150 million through an institutional placement to fund growth projects at its Plutonic Gold Belt and bolster its balance sheet. This capital injection positions the company to expand production and advance exploration without financial strain.

EBR Systems has announced a fully underwritten A$55.9 million capital raise alongside a Security Purchase Plan to fund the commercial rollout of its FDA-approved WiSE CRT System, targeting a US$3.6 billion market opportunity in cardiac resynchronization therapy.

Jupiter Energy has secured extended interest-free terms on its debt and capped repayments as it pursues a dual listing on the Astana International Exchange, aiming to strengthen its financial footing for growth.

Koonenberry Gold has raised $5 million through a strategic placement to accelerate extensive drilling at its Enmore project and continue exploration in the Lachlan region.

Talga Group has successfully raised A$10 million through a strategic share placement to advance its Vittangi Anode Project, supported by key institutional investors and board members.

Nimy Resources has raised $2.75 million through a share placement to fast-track exploration and resource definition at its promising Block 3 gallium discovery in Western Australia amid soaring global gallium prices.

Island Pharmaceuticals has raised $3.6 million through a strategic share placement to advance its lead antiviral drug ISLA-101’s clinical development and broaden its asset portfolio ahead of pivotal Phase 2a/b trial results.

Midas Minerals has locked in $6.5 million through a two-tranche placement to fund its strategic acquisition and exploration of the Otavi Copper Project in Namibia, alongside advancing its broader project portfolio.

Noxopharm Limited has raised nearly $2.5 million by selling its entire stake in Nyrada Inc, providing non-dilutive capital to advance its HERACLES clinical trial and expand its research pipeline.